Last 48 quarters of trend data · Healthcare · Oncology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 60.28 | — | 10.09 | 16.01 | 16.91 | 10.05 | 8.35 | 18.92 | 16.93 | 30.60 | — | 18.99 | 17.64 | 19.00 | 17.29 | 187.81 | 154.46 | 33.32 | 26.38 | 116.79 | 7.22 |
| — | — | +20.8% | -15.4% | -0.1% | -67.2% | — | -0.4% | -4.0% | +61.0% | — | -89.9% | -88.6% | -43.0% | -34.4% | +60.8% | +2038.1% | +58.9% | -16.0% | +38.0% | -77.4% | |
| P/S Ratio | 4.03 | 3.96 | 3.52 | 3.82 | 3.36 | 3.13 | 2.78 | 2.85 | 2.89 | 2.84 | 3.17 | 3.67 | 3.50 | 3.55 | 3.68 | 5.04 | 4.87 | 4.54 | 4.66 | 6.04 | 4.72 |
| — | +26.6% | +26.6% | +34.2% | +16.0% | +9.9% | -12.1% | -22.4% | -17.4% | -20.0% | -13.9% | -27.1% | -28.1% | -21.6% | -21.1% | -16.5% | +3.2% | -3.5% | -29.6% | -19.0% | -22.5% | |
| P/B Ratio | 4.65 | 4.37 | 3.72 | 3.51 | 3.91 | 3.67 | 3.24 | 3.27 | 3.96 | 4.08 | 4.41 | 2.40 | 2.74 | 2.65 | 2.96 | 3.65 | 4.13 | 3.53 | 4.16 | 4.58 | 4.32 |
| — | +19.0% | +14.6% | +7.2% | -1.0% | -10.0% | -26.5% | +36.4% | +44.6% | +54.1% | +48.9% | -34.3% | -33.8% | -25.0% | -28.8% | -20.3% | -4.4% | -27.2% | -34.7% | -30.7% | -41.3% | |
| P/FCF | 35.41 | — | 11.91 | 13.55 | 9.70 | 7.84 | 131.83 | 11.41 | 9.37 | 10.59 | — | 15.46 | 24.40 | 23.87 | 11.74 | — | 17.21 | 13.91 | 26.15 | 22.27 | 50.36 |
| — | — | -91.0% | +18.7% | +3.5% | -25.9% | — | -26.2% | -61.6% | -55.6% | — | — | +41.8% | +71.6% | -55.1% | — | -65.8% | -18.9% | -40.3% | -21.9% | -41.5% | |
| EV / EBITDA | 26.80 | — | 6.78 | 11.52 | 10.54 | 8.05 | 8.71 | 10.56 | 9.37 | 17.31 | — | 21.16 | 13.18 | 10.46 | 12.79 | 76.87 | 42.89 | 19.81 | 13.47 | 29.13 | 28.43 |
| — | — | -22.1% | +9.1% | +12.5% | -53.5% | — | -50.1% | -29.0% | +65.6% | — | -72.5% | -69.3% | -47.2% | -5.0% | +163.9% | +50.9% | +48.7% | -50.6% | -20.0% | +13.5% | |
| EV / EBIT | 15.81 | — | 6.53 | 11.65 | 11.01 | 7.59 | 5.20 | 10.75 | 9.54 | 18.56 | — | 10.18 | 10.14 | 10.53 | 9.84 | 64.61 | 46.59 | 20.59 | 15.87 | 54.39 | 29.56 |
| — | — | +25.6% | +8.3% | +15.4% | -59.1% | — | +5.6% | -5.9% | +76.2% | — | -84.2% | -78.2% | -48.8% | -38.0% | +18.8% | +57.6% | +29.7% | -35.6% | -7.6% | +12.1% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 92.8% | 93.0% | 93.7% | 91.8% | 92.0% | 92.8% | 93.5% | 93.0% | 92.5% | 92.4% | 92.7% | 93.1% | 93.1% | 93.5% | 92.8% | 93.0% | 93.6% | 93.4% | 94.4% | 94.2% | 94.9% |
| — | +0.3% | +0.2% | -1.4% | -0.6% | +0.3% | +0.9% | -0.0% | -0.7% | -1.1% | -0.2% | +0.1% | -0.5% | +0.1% | -1.7% | -1.3% | -1.4% | -1.8% | -0.2% | -1.0% | -0.5% | |
| Operating Margin | 26.1% | -45.5% | 41.7% | 25.5% | 25.5% | 31.6% | 25.6% | 20.6% | 25.2% | 12.8% | -45.8% | 10.4% | 18.5% | 23.4% | 20.3% | 3.1% | 7.6% | 16.8% | 27.9% | 15.9% | 12.8% |
| — | -244.1% | +63.0% | +23.8% | +1.0% | +145.9% | +155.8% | +97.3% | +36.5% | -45.0% | -325.7% | +240.6% | +144.3% | +39.0% | -27.3% | -80.7% | -41.1% | -42.0% | +39.9% | -2.7% | -38.3% | |
| Net Margin | 25.0% | -50.4% | 35.0% | 23.8% | 19.9% | 31.1% | 33.3% | 15.0% | 17.1% | 9.4% | -42.6% | 19.2% | 19.8% | 18.6% | 21.3% | 2.7% | 3.1% | 13.7% | 17.7% | 5.2% | 65.3% |
| — | -262.3% | +5.0% | +58.6% | +16.3% | +231.9% | +178.2% | -21.9% | -14.0% | -49.8% | -299.8% | +617.2% | +546.1% | +36.0% | +20.4% | -48.2% | -95.3% | -38.7% | -16.4% | -41.5% | +244.3% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 29.9% | -13.1% | 9.8% | 5.7% | 6.1% | 9.6% | 10.3% | 4.4% | 6.1% | 3.5% | -10.6% | 3.2% | 4.0% | 3.5% | 4.4% | 0.5% | 0.7% | 2.7% | 4.1% | 1.0% | 16.3% |
| — | -236.2% | -4.7% | +27.3% | +0.3% | +178.6% | +197.5% | +38.8% | +53.0% | -2.5% | -339.6% | +552.0% | +500.1% | +30.5% | +8.9% | -50.6% | -95.9% | -54.6% | -23.0% | -50.4% | +172.0% | |
| ROA | 20.7% | -10.4% | 7.7% | 4.2% | 4.5% | 7.0% | 7.0% | 2.8% | 3.8% | 2.2% | -7.5% | 2.4% | 3.1% | 2.7% | 3.4% | 0.4% | 0.5% | 2.1% | 3.1% | 0.8% | 12.3% |
| — | -248.3% | +10.0% | +50.1% | +17.0% | +217.2% | +192.9% | +16.0% | +26.0% | -19.1% | -322.3% | +553.4% | +508.9% | +30.6% | +8.9% | -51.0% | -95.9% | -53.6% | -21.2% | -48.7% | +183.0% | |
| ROIC | 51.1% | -22.1% | 23.1% | 11.4% | 13.2% | 14.4% | 11.6% | 9.1% | 12.0% | 5.5% | -17.4% | 3.4% | 7.5% | 9.5% | 8.7% | 1.2% | 3.5% | 6.3% | 11.4% | 5.1% | 5.6% |
| — | -253.7% | +99.8% | +25.3% | +9.4% | +159.5% | +166.7% | +170.7% | +60.9% | -41.6% | -298.9% | +184.3% | +116.1% | +49.7% | -23.6% | -76.9% | -38.5% | -57.3% | +23.6% | -22.1% | -52.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| — | -25.3% | -40.7% | -48.2% | +6.4% | -22.9% | -18.8% | +69.6% | +71.2% | +49.0% | +49.4% | -23.1% | -22.2% | -22.4% | -21.4% | -21.0% | -20.2% | -28.1% | -30.8% | -32.5% | -34.7% | |
| Debt / EBITDA | 0.05 | — | 0.05 | 0.10 | 0.17 | 0.09 | 0.13 | 0.18 | 0.14 | 0.22 | — | 0.33 | 0.18 | 0.16 | 0.19 | 0.91 | 0.47 | 0.27 | 0.16 | 0.33 | 0.36 |
| — | — | -58.4% | -46.1% | +25.1% | -58.1% | — | -45.1% | -25.7% | +34.2% | — | -64.1% | -61.0% | -40.5% | +15.5% | +176.0% | +31.5% | +55.6% | -44.8% | -19.1% | +33.2% | |
| Current Ratio | 3.32 | 3.84 | 4.66 | 3.68 | 3.32 | 3.20 | 2.85 | 2.04 | 1.97 | 1.87 | 1.92 | 3.47 | 3.75 | 3.91 | 3.81 | 3.95 | 3.54 | 3.80 | 3.91 | 3.71 | 3.65 |
| — | +20.2% | +63.6% | +80.6% | +68.1% | +70.8% | +48.4% | -41.3% | -47.3% | -52.2% | -49.6% | -12.0% | +5.9% | +3.1% | -2.6% | +6.4% | -3.1% | -3.6% | -1.4% | -5.5% | -2.4% | |
| Quick Ratio | 3.25 | 3.75 | 4.58 | 3.60 | 3.25 | 3.13 | 2.78 | 2.00 | 1.94 | 1.82 | 1.84 | 3.43 | 3.69 | 3.86 | 3.78 | 3.91 | 3.50 | 3.75 | 3.85 | 3.67 | 3.62 |
| — | +19.6% | +64.4% | +80.0% | +67.7% | +71.8% | +50.9% | -41.6% | -47.6% | -52.8% | -51.2% | -12.3% | +5.5% | +3.0% | -1.9% | +6.4% | -3.2% | -4.0% | -2.2% | -5.9% | -2.6% | |
| Interest Coverage | 686.52 | -1137.59 | 1294.48 | 604.87 | 671.00 | 815.71 | 940.41 | 355.83 | 749.74 | 203.23 | -592.27 | 550.21 | 338.01 | 376.28 | 424.82 | 111.57 | 121.86 | 232.81 | 339.32 | 104.73 | 160.60 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying INCY stock.
Incyte Corporation's current P/E is 60.3x. The average P/E over the last 3 quarters is 14.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Incyte Corporation's current operating margin is 26.1%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Incyte Corporation's business trajectory between earnings reports.